Research programme: neuropeptide Y modulators - LundbeckAlternative Names: Lu AA33810
Latest Information Update: 08 Feb 2011
At a glance
- Originator Lundbeck Research USA
- Mechanism of Action Neuropeptide Y receptor agonists; Neuropeptide Y receptor antagonists; Neuropeptide Y5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Drug abuse; Major depressive disorder; Pain